BCRX — BioCryst Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $1.55bn
- $2.06bn
- $450.71m
- 17
- 47
- 82
- 47
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 617.08 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.43 | ||
| EV to EBITDA | 4,388.08 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -0.77% | ||
| Return on Equity | n/a | ||
| Operating Margin | -0.56% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 17.81 | 157.17 | 270.83 | 331.41 | 450.71 | 564 | 639.68 | 55.97% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with hereditary angioedema and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.
Directors
- Robert Ingram NEC
- Jon Stonehouse CEO (60)
- Anthony Doyle CFO (41)
- John Bluth OTH
- Yarlagadda Babu OTH (68)
- Charles Gayer OTH (50)
- Jinky Rosselli OTH
- William Sheridan OTH (66)
- Helen Thackray OTH (52)
- Alane Barnes SEC (55)
- Steven Galson DRC
- Amy Mckee DRC
- Vincent Milano DRC (57)
- Machelle Sanders DRC (57)
- George Abercrombie IND (66)
- Stephen Aselage IND (69)
- Theresa Heggie IND (60)
- Nancy Hutson IND (71)
- Kenneth Lee IND (73)
- Alan Levin IND (59)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 15th, 1991
- Public Since
- March 4th, 1994
- No. of Shareholders
- 147
- No. of Employees
- 580
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 208,960,020
- Address
- 4505 Emperor Blvd Ste 200, DURHAM, 27703-8457
- Web
- https://www.biocryst.com/
- Phone
- +1 9198591302
- Auditors
- Ernst & Young LLP
Upcoming Events for BCRX
BioCryst Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2025 BioCryst Pharmaceuticals Inc Earnings Release
Similar to BCRX
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the BioCryst Pharmaceuticals share price?
As of Today at 19:35 UTC, shares in BioCryst Pharmaceuticals are trading at $7.40. This share price information is delayed by 15 minutes.
How has the BioCryst Pharmaceuticals share price performed this year?
Shares in BioCryst Pharmaceuticals last closed at $7.40 and the price had moved by +61.57% over the past 365 days. In terms of relative price strength the BioCryst Pharmaceuticals share price has outperformed the S&P500 Index by +51.92% over the past year.
What are the analyst and broker recommendations for BioCryst Pharmaceuticals?
The overall consensus recommendation for BioCryst Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the BioCryst Pharmaceuticals dividend yield?
BioCryst Pharmaceuticals does not currently pay a dividend.
Does BioCryst Pharmaceuticals pay a dividend?
BioCryst Pharmaceuticals does not currently pay a dividend.
When does BioCryst Pharmaceuticals next pay dividends?
BioCryst Pharmaceuticals does not currently pay a dividend.
How do I buy BioCryst Pharmaceuticals shares?
To buy shares in BioCryst Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of BioCryst Pharmaceuticals?
As of the previous close price of $7.40, shares in BioCryst Pharmaceuticals had a market capitalisation of $1.55bn.
Where are BioCryst Pharmaceuticals shares listed?
Here are the trading details for BioCryst Pharmaceuticals:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: BCRX
What kind of share is BioCryst Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum BioCryst Pharmaceuticals is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a BioCryst Pharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in BioCryst Pharmaceuticals is $15.42. That is 108.38% above the last closing price of $7.40.
Analysts covering BioCryst Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$0.08 for the next financial year.
Find out moreWhat is the trend in the BioCryst Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BioCryst Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +7.61%.
As of the last closing price of $7.40, shares in BioCryst Pharmaceuticals were trading -3.95% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the BioCryst Pharmaceuticals PE Ratio?
The BioCryst Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 617.08. The shares last closed at $7.40.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals' management team is headed by:
- Robert Ingram - NEC
- Jon Stonehouse - CEO
- Anthony Doyle - CFO
- John Bluth - OTH
- Yarlagadda Babu - OTH
- Charles Gayer - OTH
- Jinky Rosselli - OTH
- William Sheridan - OTH
- Helen Thackray - OTH
- Alane Barnes - SEC
- Steven Galson - DRC
- Amy Mckee - DRC
- Vincent Milano - DRC
- Machelle Sanders - DRC
- George Abercrombie - IND
- Stephen Aselage - IND
- Theresa Heggie - IND
- Nancy Hutson - IND
- Kenneth Lee - IND
- Alan Levin - IND